Drug Resistant Epilepsy - Pipeline Insight, 2022

Drug Resistant Epilepsy - Pipeline Insight, 2022

DelveInsight’s, Drug Resistant Epilepsy - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Drug Resistant Epilepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Drug Resistant Epilepsy Understanding

Drug resistant epilepsy (DRE) is defined as the persistence of seizures despite at least two syndrome-adapted antiseizure drugs (ASD) used at efficacious daily dose. Despite the increasing number of available ASD, about a third of patients with epilepsy still suffer from drug resistance. Several factors are associated with the risk of evolution to DRE in patients with newly diagnosed epilepsy, including epilepsy onset in the infancy, intellectual disability, symptomatic epilepsy and abnormal neurological exam.

The prevalence of DRE is 30% (95% CI: 19–42%). Its incidence varies from 15% (95% CI: 11–19%) in children to 34% (95% CI: 6–62%) in adults18 without variation across geographic areas. Among patients with newly diagnosed epilepsy followed for at least two years in the Glasgow cohort, 36% were not seizure free the last year of follow-up.

""Drug Resistant Epilepsy - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Drug Resistant Epilepsy pipeline landscape is provided which includes the disease overview and Drug Resistant Epilepsy treatment guidelines. The assessment part of the report embraces, in depth Drug Resistant Epilepsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Drug Resistant Epilepsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Drug Resistant Epilepsy. The therapies under development are focused on novel approaches to treat/improve Drug Resistant Epilepsy.

Drug Resistant Epilepsy Emerging Drugs

Fintepla: Zogenix

Fintepla (fenfluramine) oral solution is a prescription medication approved by the FDA and EMA, and under regulatory review with PMDA (Japan), for the treatment of seizures associated with Dravet syndrome in patients two years of age and older.

ABI-009: Aadi Bioscience

ABI-009 is an mTOR inhibitor complexed with human albumin that has significantly higher tumor accumulation, mTOR target suppression and improved efficacy over other mTOR inhibitors in preclinical models.

Further product details are provided in the report……..

Drug Resistant Epilepsy: Therapeutic Assessment

This segment of the report provides insights about the Drug Resistant Epilepsy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Drug Resistant Epilepsy

There are approx. 10+ key companies which are developing the therapies Drug Resistant Epilepsy. The companies which have their Drug Resistant Epilepsy drug candidates in the most advanced stage, i.e phase II include UCB

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Drug Resistant Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Drug Resistant Epilepsy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Drug Resistant Epilepsy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Drug Resistant Epilepsy drugs.

Drug Resistant Epilepsy Report Insights

• Drug Resistant Epilepsy Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Drug Resistant Epilepsy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Drug Resistant Epilepsy drugs?
• How many Drug Resistant Epilepsy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Drug Resistant Epilepsy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Drug Resistant Epilepsy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Drug Resistant Epilepsy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ES Therapeutics
• PTC Therapeutics
• Aadi Bioscience
• MGC Pharma
• UCB
• Zogenix

Key Products

• ES 481
• Vatiquinone
• ABI-009
• MGCND00EP1
• Padsevonil
• Fintepla


Please Note: It will take 7-10 business days to complete the report upon order confirmation.